ZBIO Maintain Outperform and $45 PT ahead of AMGN earnings as reiterate Wedbush's case for a valuation of $2.4B ($26/sh) for ZBIO's obexelim
ZBIO Maintain Outperform and $45 PT ahead of AMGN earnings as reiterate Wedbush's case for a valuation of $2.4B ($26/sh) for ZBIO's obexelimab in IgG4-RD alone @ Wedbush
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.